Lakefront Biotherapeutics American Depositary Shares
LKFT
48 hedge funds and large institutions have $628M invested in Lakefront Biotherapeutics American Depositary Shares in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
26% more funds holding
Funds holding: 38 → 48 (+10)
16% more capital invested
Capital invested by funds: $543M → $628M (+$85.2M)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.11% less ownership
Funds ownership: 14.94% → 14.82% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$7.44M |
| 2 |
O
OrbiMed
New York
|
+$5.93M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.45M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.93M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.45M |
| 3 |
DM
Deerfield Management
New York
|
-$1.97M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$947K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$896K |
LKFT Hedge Fund Activity: Q3 2016 in Review
48 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2016, worth a combined $628M — up 16% from $543M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LKFT positions and 2 closed out — a net gain of 10 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $7.44M. The largest seller was Wellington Management Group, cutting an estimated $16.8M.
- 48 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2016, up from 38 in Q2 2016.
- Funds reported $628M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2016, up 16% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2016 and 2 closed out, a net change of +10 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2016 was Renaissance Technologies, an estimated $7.44M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2016 was Wellington Management Group, an estimated $16.8M sold.
Based on aggregated 13F filings for Q3 2016.